Unknown PHASE2 INTERVENTIONAL 2-arm NCT02095743

Tolerance of PICC Line Versus Implanted Port for Adjuvant Chemotherapy in Early Breast Cancer (EPIC)

Phase II Randomised Study Comparing the Tolerance of PICC Line (Peripherally Inserted Central Catheter) and Implanted Port for Adjuvant Chemotherapy in HER2-negative Early Breast Cancer

Sponsor: Centre Henri Becquerel

Conditions Early Stage Breast Carcinoma

Interventions Use of a PICC line for chemo administration (PowerPICC SOLO²) implanted port for chemo administration (X-port isp)

Updated 7 times since 2017 Last updated: Jul 20, 2018 Started: Apr 30, 2014 Primary completion: Dec 31, 2018 Completion: Mar 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Early Stage Breast Carcinoma and is currently ongoing. Centre Henri Becquerel leads this study, which shows 7 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Aug 2020 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Active Not Recruiting → Unknown Status
Aug 2018 — Aug 2020 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting

▶ Show 2 earlier versions

Jun 2018 — Aug 2018 [monthly]

Recruiting PHASE2
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centre Henri Becquerel

Data source: Centre Henri Becquerel

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rouen, France